ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 489,35
0,59%
Dow Jones
42 600,66
-0,25%
DAX
20 340,57
0,65%
Brent Oil
77,01
1,18%
Bitcoin
96 490,88
-5,67%
Registration Strip Icon for charts Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ

  6. Poseida Therapeutics Inc (PSTX) Cours

Poseida Therapeutics Inc

Poseida Therapeutics Inc (PSTX)

NASDAQ
9,565
0,005
( 0,05% )
Mis à jour : 20:24:22
Retardé de 15 minutes

Outils de qualité professionnelle, pour des investisseurs individuels.

Premium

Statistiques et détails clés

Dernier
9,565
Prix Achat
9,56
Prix Vente
9,57
Volume échangé
2 166 914
9,56 Fourchette du Jour 9,67
1,87 Plage de 52 semaines 9,67
Cap du marché
932,253M
Clôture Veille
9,56
Ouverture
9,58
Dernière Transaction
839
@
9.565
Dernière heure de transaction
20:24:22
Volume financier
US$ 20 811 707
VWAP
9,6043
Volume moyen (3 m)
1 422 290
Actions en circulation
97 465 024
Rendement du Dividende
-
Ratio Cours sur Bénéfices
-7,56
Bénéfice par action (BPA)
-1,27
Chiffre d'affairess
64,7M
Bénéfice net
-123,43M

À propos de Poseida Therapeutics Inc

Poseida Therapeutics Inc is a clinical-stage biopharmaceutical company focused on leveraging non-viral gene engineering technologies to create life-saving therapeutics for patients with a high unmet delivery technology. It has built a pipeline of autologous and allogeneic chimeric antigen receptor T... Poseida Therapeutics Inc is a clinical-stage biopharmaceutical company focused on leveraging non-viral gene engineering technologies to create life-saving therapeutics for patients with a high unmet delivery technology. It has built a pipeline of autologous and allogeneic chimeric antigen receptor T cell, or CAR-T, product candidates, initially focused on the treatment of hematological malignancies and solid tumours. Show more

Secteur
Biological Pds,ex Diagnstics
Industrie
Biological Pds,ex Diagnstics
Site Web
www.poseida.com
Siège social
Wilmington, Delaware, USA
Fondé
-
Poseida Therapeutics Inc est coté dans le secteur Biological Pds,ex Diagnstics de la NASDAQ avec le ticker PSTX. Le dernier cours de clôture d'Poseida Therapeutics était de US$9,56. Au cours de la dernière année, les actions de Poseida Therapeutics ont été négociées dans une fourchette de prix de US$ 1,87 à US$ 9,67.

Poseida Therapeutics compte actuellement 97 465 024 actions en circulation. La capitalisation boursière d'Poseida Therapeutics est de US$931,77 million. Poseida Therapeutics a un ratio cours/bénéfice (ratio PE) de -7.56.

Flux d'options Poseida Therapeutics (PSTX)

Voir le flux d'options complet

Flux global

Haussier

Prime nette

402k

Calls / Puts

100,00%

Ach. / Vent.

300,00%

OTM / ITM

0,00%

Sweeps Ratio

0,00%

PSTX Dernières nouvelles

Plus de nouvelles

Form SC 14D9/A - Solicitation, recommendation statements: [Amend]

il y a 7 heures
Edgar (US Regulatory)

Form SC 14D9/A - Solicitation, recommendation statements: [Amend]

il y a 21 heures
Edgar (US Regulatory)

Form SC TO-T/A - Tender offer statement by Third Party: [Amend]

27 Décembre 2024
Edgar (US Regulatory)

Form SC 14D9 - Solicitation, recommendation statements

09 Décembre 2024
Edgar (US Regulatory)

Poseida Therapeutics Highlights Positive Interim Phase 1 Results for P-BCMA-ALLO1 and Preclinical Data for Dual CAR-T P-CD19CD20-ALLO1 at the 66th American Society of Hematology (ASH) Annual Meeting

Poseida Therapeutics Highlights Positive Interim Phase 1 Results for P-BCMA-ALLO1 and Preclinical Data for Dual CAR-T P-CD19CD20-ALLO1 at the 66th American Society of Hematology (ASH) Annual...

09 Décembre 2024
PR Newswire (US)

Form SC14D9C - Written communication relating to third party tender offer

27 Novembre 2024
Edgar (US Regulatory)

Form SC14D9C - Written communication relating to third party tender offer

26 Novembre 2024
Edgar (US Regulatory)

Form 8-K - Current report

26 Novembre 2024
Edgar (US Regulatory)

Poseida Therapeutics, Inc. Announces Agreement to be Acquired by Roche Holdings, Inc.

Poseida Therapeutics, Inc. Announces Agreement to be Acquired by Roche Holdings, Inc. PR Newswire SAN DIEGO, Nov. 26, 2024 Poseida stockholders to receive up to $13.00 per share in cash...

26 Novembre 2024
PR Newswire (US)

Form 8-K - Current report

14 Novembre 2024
Edgar (US Regulatory)
PériodeVariationVariation %Ouver.HautBasMoyenne Vol. Quot.VWAP
10.0650.6842105263169.59.679.3923469379.50861731CS
40.1451.539278131639.429.679.3612212269.48547793CS
127.075284.1365461852.499.672.3214222908.14658821CS
266.535215.6765676573.039.672.328902776.75211196CS
526.435205.5910543133.139.671.877592135.28748666CS
1563.02546.253822636.549.671.547198064.15012031CS
260-7.435-43.73529411761717.621.545711345.1037563CS

PSTX - Frequently Asked Questions (FAQ)

What is the current Poseida Therapeutics share price?
The current share price of Poseida Therapeutics is US$ 9,565
How many Poseida Therapeutics shares are in issue?
Poseida Therapeutics has 97 465 024 shares in issue
What is the market cap of Poseida Therapeutics?
The market capitalisation of Poseida Therapeutics is USD 931,77M
What is the 1 year trading range for Poseida Therapeutics share price?
Poseida Therapeutics has traded in the range of US$ 1,87 to US$ 9,67 during the past year
What is the PE ratio of Poseida Therapeutics?
The price to earnings ratio of Poseida Therapeutics is -7,56
What is the cash to sales ratio of Poseida Therapeutics?
The cash to sales ratio of Poseida Therapeutics is 14,41
What is the reporting currency for Poseida Therapeutics?
Poseida Therapeutics reports financial results in USD
What is the latest annual turnover for Poseida Therapeutics?
The latest annual turnover of Poseida Therapeutics is USD 64,7M
What is the latest annual profit for Poseida Therapeutics?
The latest annual profit of Poseida Therapeutics is USD -123,43M
What is the registered address of Poseida Therapeutics?
The registered address for Poseida Therapeutics is 251 LITTLE FALLS DRIVE, WILMINGTON, DELAWARE, 19808
What is the Poseida Therapeutics website address?
The website address for Poseida Therapeutics is www.poseida.com
Which industry sector does Poseida Therapeutics operate in?
Poseida Therapeutics operates in the BIOLOGICAL PDS,EX DIAGNSTICS sector

Moteurs

Voir tout
  • Volume
  • % Gagnants
  • % Perdants
SymbolePrixVol.
HOTHHoth Therapeutics Inc
US$ 2,4593
(200,06%)
380,37M
DATSDatChat Inc
US$ 4,93
(151,53%)
118,85M
SPISPI Energy Company Ltd
US$ 1,00
(132,56%)
115,62M
SVMHSRIVARU Holding Ltd
US$ 0,087679
(89,37%)
1,14B
RIMEAlgorhythm Holdings Inc
US$ 0,2221
(53,38%)
636,56M
DHAIDIH Holdings US Inc
US$ 1,82
(-37,67%)
1,33M
CISOCISO Global Inc
US$ 1,70
(-37,04%)
393,16k
SLRNACELYRIN Inc
US$ 2,2392
(-35,84%)
9,92M
AMSTAmesite Inc
US$ 2,74
(-32,35%)
794,17k
HCTIHealthcare Triangle Inc
US$ 1,25
(-26,47%)
234,66k
XTIAXTI Aerospace Inc
US$ 0,1098
(24,77%)
2,24B
SVMHSRIVARU Holding Ltd
US$ 0,087679
(89,37%)
1,14B
CEROCERo Therapeutics Holdings Inc
US$ 0,05825
(37,71%)
837,95M
RIMEAlgorhythm Holdings Inc
US$ 0,2221
(53,38%)
636,56M
HOTHHoth Therapeutics Inc
US$ 2,4593
(200,06%)
380,37M

Forums

Afficher les forums
Aucune Discussion Trouvée
Ajouter une Discussion

Dernières Valeurs Consultées

NASDAQ
PSTX
Poseida Therapeutics
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2025 ADVFN PLC - Tous droits réservés